Dear Dr. Murbach:

The Food and Drug Administration (FDA, we) is granting the request on behalf of Phynova Group Limited (Phynova) to cease our evaluation of GRN 000894, which we filed on January 29, 2020. We received this request on September 2, 2020.

The subject of the notice is white mulberry (*Morus alba* L.) leaf extract for use as an ingredient in a variety of food categories at levels ranging from 120 mg to 294 mg/serving. The notice informs FDA of Phynova’s view that white mulberry leaf extract is GRAS through scientific procedures.

In an email dated June 29, 2020, we informed Phynova that L-leucine has not been approved as a food additive or concluded to be GRAS for the use described in GRN 000894. In response to our questions seeking clarification on the use of L-leucine in the manufacture of white mulberry leaf extract, Phynova offered to submit an amendment that would remove L-leucine from the manufacturing process. We recommended that Phynova request that we cease our evaluation of GRN 000894 and resubmit the notice with a revised manufacturing process, specifications, dietary exposure estimate, and safety narrative, as appropriate.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 000894 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan Carlson, Ph.D.
Director
Division of Food Ingredients
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition